# US 2016/0354341 A1 · Therapeutic formulations and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354341 A1
- Document ID: US20160354341A1
- Status: Published application
- Kind: A1
- Application number: 15/177,150
- Filed: 2016-06-08
- Published: 2016-12-08
- Earliest claimed: 2015-06-08
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Steven Earl Patterson; Herbert Tsukasa Nagasawa; Robert Vince; Alexandre Monteil
- Web page: https://patentgrep.com/patent/US20160354341A1

## CPC

- A61K 31/385: having two or more sulfur atoms in the same ring
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides compositions and methods for treating cyanide poisoning.

## Claims

### Claim 1

A pharmaceutical composition comprising, sulfanegen lysine, lysine hydrochloride, and water.

### Claim 2

A pharmaceutical composition prepared by combining sulfanegen lysine, lysine hydrochloride, and water.

### Claim 3

A pharmaceutical composition prepared by combining sulfanegenic acid and a solution of lysine in water.

### Claim 4

A pharmaceutical composition prepared by combining sulfanegenic acid and a solution prepared by combining water, lysine and lysine hydrochloride.

### Claim 5

A pharmaceutical composition comprising sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid.

### Claim 6

A pharmaceutical composition prepared by combining sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the molar ratio of sulfanegenic acid:lysine is about 1:2

### Claim 8 (depends on 1)

The composition of claim 1 wherein the molar ratio of sulfanegenic acid:lysine:lysine hydrochloride is about 1:2:0.4

### Claim 9 (depends on 1)

The composition of claim 1, which is formulated for im administration.

### Claim 10

A method comprising combining a) a solution prepared by combining water, lysine and lysine hydrochloride and b) sulfanegenic acid to provide a resulting solution.

### Claim 11

A method comprising combining a) water and b) sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid to provide a resulting solution.

### Claim 12 (depends on 10)

The method of claim 10 further comprising administering the resulting solution to an animal.

### Claim 13 (depends on 12)

The method of claim 12 wherein the resulting solution is administered to the animal at least 1 hour after combining.

### Claim 14 (depends on 12)

The method of claim 12 wherein the resulting solution is administered to the animal at least 15 hours after combining.

### Claim 15 (depends on 1)

The composition of claim 1, which is formulated for iv administration.

### Claim 16

A kit comprising a) a solution prepared by combining water, lysine and lysine hydrochloride; b) sulfanegenic acid solid; and instructions for combining the solution and the solid to provide a composition suitable for treating cyanide poisoning.

### Claim 17

A kit comprising a) sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid; and instructions for combining the sulfanegenic acid solid, lysine solid, and lysine hydrochloride solid with water to provide a composition suitable for treating cyanide poisoning.

### Claim 18 (depends on 1)

The composition of claim 1 having a pH of greater than about 4.

### Claim 19 (depends on 1)

The composition of claim 1 having a pH of less than about 5.

### Claim 20 (depends on 1)

The composition of claim 1, which is formulated for io administration.

### Claim 21

A nanoparticle comprising sulfanegen lysine and lysine hydrochloride.

### Claim 22 (depends on 21)

A nanoparticle suspension comprising a plurality of nanoparticles as described in claim 21.

### Claim 23 (depends on 21)

A pharmaceutical composition comprising a plurality of nanoparticles as described in claim 21 and a pharmaceutically acceptable carrier.
